Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LBM415

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

NVP PDF 713

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pharmacokinetics and Unexpected Safety Issues of LBM415, a Novel Oral Peptide Deformylase Inhibitor
Peptide deformylase (PDF) inhibitors represent a potential new class of antibiotics targeting a large number of bacterial species… Expand
2009
2009
In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models
ABSTRACT LBM415 is an antibacterial agent belonging to the peptide deformylase inhibitor class of compounds. It has previously… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2007
2007
Reduced Susceptibility of Haemophilus influenzae to the Peptide Deformylase Inhibitor LBM415 Can Result from Target Protein Overexpression Due to Amplified Chromosomal def Gene Copy Number
ABSTRACT Previous genetic analysis of Haemophilus influenzae revealed two mechanisms associated with decreased susceptibility to… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2006
2006
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
OBJECTIVES To evaluate the spectrum of activity and potency of LBM415, the first of the peptide deformylase inhibitor (PDFI… Expand
  • table 1
  • table 2
  • table 2
  • table 2
  • table 3
Highly Cited
2005
Highly Cited
2005
Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance
ABSTRACT LBM415 (NVP PDF-713) is the first member of the peptide deformylase (PDF) inhibitor class being developed for clinical… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • table 3
2005
2005
Role of the AcrAB-TolC Efflux Pump in Determining Susceptibility of Haemophilus influenzae to the Novel Peptide Deformylase Inhibitor LBM415
ABSTRACT Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2005
2005
Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia
ABSTRACT Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2005
2005
In Vitro and Intracellular Activities of LBM415 (NVP PDF-713) against Legionella pneumophila
ABSTRACT LBM415 activity against extracellular and intracellular Legionella pneumophila was studied. The LBM415 MIC50 for 20… Expand
  • figure 1
  • table 1
2004
2004
Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents
ABSTRACT The MICs of LBM415, a new peptide diformylase inhibitor, were ≤0.06 to 4.0 μg/ml for 258 isolates of Staphylococcus… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2004
2004
Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
ABSTRACT The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 μg/ml for 300… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE